HER2-Positive Breast Carcinoma — Trials

HER2-Positive Breast Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 140
Recruiting: 73
Ph III recruiting: 15
Growth YoY: +11.5%
Industry share: 19%
Top sponsor: Fudan University
Termination share: 43.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (52)

clinicaltrialsPublishedShowing 151–167 of 167 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05710666	Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)	active not recruiting	Phase 2	11	Cancer Trials IrelandNETWORK	1	Aug 5, 2024	clinicaltrials
NCT05635487	A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients	recruiting	Phase 2	65	Shengjing HospitalOTHER	1	Jul 5, 2024